Want to see HK:2575 full AI Analyst Report?
Xuanzhu Biopharmaceutical Co., Ltd. Class H (2575) Financial Statements
Xuanzhu Biopharmaceutical Co., Ltd. Class H Financial Overview
Xuanzhu Biopharmaceutical Co., Ltd. Class H's market cap is currently $4.45B. The company's EPS TTM is $-0.48; its P/E ratio is -18.04; Xuanzhu Biopharmaceutical Co., Ltd. Class H is scheduled to report earnings on ―, and the estimated EPS forecast is $―. See an overview of income statement, balance sheet, and cash flow financials.
| Dec 25 | Dec 24 | Dec 23 | Dec 22 | Dec 21 | |
|---|---|---|---|---|---|
| Income Statement | |||||
| Total Revenue | $ 56.15M | $ 32.63M | $ 32.04K | $ 0.00 | $ 0.00 |
| Gross Profit | $ 21.80M | $ -12.60M | $ -35.52M | $ -30.16M | $ 0.00 |
| Operating Income | $ -253.14M | $ -611.27M | $ -374.71M | $ -580.24M | $ -565.50M |
| EBITDA | $ -220.55M | $ -566.36M | $ -295.28M | $ -563.77M | $ -489.29M |
| Net Income | $ -266.26M | $ -603.29M | $ -332.12M | $ -595.70M | $ -566.28M |
| Balance Sheet | |||||
| Cash & Short-Term Investments | $ 765.43M | $ 294.13M | $ 495.15M | $ 792.98M | $ 1.51B |
| Total Assets | $ 1.83B | $ 1.27B | $ 1.45B | $ 1.63B | $ 2.30B |
| Total Debt | $ 720.64K | $ 1.57M | $ 18.79M | $ 32.82M | $ 36.02M |
| Net Debt | $ -764.71M | $ -174.87M | $ -138.54M | $ -218.80M | $ -1.34B |
| Total Liabilities | $ 300.83M | $ 255.31M | $ 232.05M | $ 130.75M | $ 111.91M |
| Stockholders' Equity | $ 1.53B | $ 1.02B | $ 1.22B | $ 1.50B | $ 2.18B |
| Cash Flow | |||||
| Free Cash Flow | $ -223.60M | $ -105.22M | $ -130.05M | $ -501.15M | $ -597.99M |
| Operating Cash Flow | $ -222.97M | $ -104.67M | $ -128.13M | $ -449.15M | $ -504.75M |
| Investing Cash Flow | $ 121.20M | $ 143.04M | $ 49.43M | $ -579.14M | $ 59.83M |
| Financing Cash Flow | $ 675.14M | $ -13.47M | $ -10.94M | $ -14.14M | $ 1.05B |
Currency in HKD